全文获取类型
收费全文 | 14228篇 |
免费 | 823篇 |
国内免费 | 492篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 164篇 |
妇产科学 | 90篇 |
基础医学 | 439篇 |
口腔科学 | 49篇 |
临床医学 | 1556篇 |
内科学 | 1846篇 |
皮肤病学 | 59篇 |
神经病学 | 319篇 |
特种医学 | 342篇 |
外国民族医学 | 1篇 |
外科学 | 3009篇 |
综合类 | 1621篇 |
一般理论 | 1篇 |
预防医学 | 1151篇 |
眼科学 | 91篇 |
药学 | 2688篇 |
12篇 | |
中国医学 | 530篇 |
肿瘤学 | 1528篇 |
出版年
2024年 | 36篇 |
2023年 | 183篇 |
2022年 | 406篇 |
2021年 | 454篇 |
2020年 | 475篇 |
2019年 | 371篇 |
2018年 | 421篇 |
2017年 | 401篇 |
2016年 | 447篇 |
2015年 | 415篇 |
2014年 | 943篇 |
2013年 | 903篇 |
2012年 | 855篇 |
2011年 | 936篇 |
2010年 | 767篇 |
2009年 | 797篇 |
2008年 | 805篇 |
2007年 | 812篇 |
2006年 | 677篇 |
2005年 | 563篇 |
2004年 | 444篇 |
2003年 | 428篇 |
2002年 | 319篇 |
2001年 | 304篇 |
2000年 | 218篇 |
1999年 | 204篇 |
1998年 | 186篇 |
1997年 | 157篇 |
1996年 | 161篇 |
1995年 | 147篇 |
1994年 | 140篇 |
1993年 | 78篇 |
1992年 | 109篇 |
1991年 | 87篇 |
1990年 | 83篇 |
1989年 | 74篇 |
1988年 | 55篇 |
1987年 | 64篇 |
1986年 | 74篇 |
1985年 | 88篇 |
1984年 | 96篇 |
1983年 | 36篇 |
1982年 | 55篇 |
1981年 | 44篇 |
1980年 | 38篇 |
1979年 | 30篇 |
1978年 | 33篇 |
1977年 | 30篇 |
1976年 | 34篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
Objective To elucidate the effect of FasL gene expression on the proliferation and apoptosis of hypoxic rectal carcinoma cells. Methods The normoxic expression level of FasL in HR-8348 subtype cells (HR-8348B, HR-8348L, HR-8348F and HR-8348As) with different invasive power were verified by Western blot. Hypoxia models for HR-8348B, HR-8348L, HR-8348F and HR-8348As were constructed with chemical modeling, then the FasL levels in all groups at 12 h after hypoxia were quantitated by Western blot. Distribution of different cell life cycles was determined with flow cytometry. Cell reproductive activities were detected with MTT method, and cell apoptesis was assessed with TUNEL. Results FasL protein was pigmentized at the position of 40 000 by Western blot, and the expression level of FasL was significantly higher in HR-8348F cells than those in HR-8348B, HR-8348L and HR-8348As cells(F=361.149, P<0.01) in normoxia. At 12 h after hypoxia, the FasL level was also significantly higher in HR-8348F cells than those in other groups (F=278.766, P<0.01), but was not markedly different as compared to themselves in normoxia (t=1.762, P>0.05). The proliferation index was significantly higher in HR-8348F (60.43±3.72) than those in HR-8348B (40.01±3.30), HR-8348L (41.30±4.06) and HR-8348As cells (35.87±4.39), respectively (F=39.477, P<0.01). However, both inhibition rate of proliferation and apoptotic index were remarkably lower in HR-8348F (17.30±1.98 and 13.10±1.04) than those in HR-834B (33.70±4.33 and 21.60±1.31), HR-8348L (34.20±3.92 and 20.10±1.15), and HR-8348As (38.00±4.55 and 23.90±1.23), respectively (F=28.811 and 76.462, respectively, P<0.01). Conclusion The expression enhancement of intracellular FasL in rectal carcinoma in hypoxia can lead to accelerated proliferation and reduced apeptosis of cells, which will promote tumor cells to adapt microenvironmental hypoxia. 相似文献
22.
为了解孕妇硬膜外给局麻药的药代动力学,选择20名实施剖宫产手术的健康临产妇,随机分成硬膜外腔给予了哌卡因组(B1组)和给予利多卡因组(L组)。另外, 6例非妊娠患者硬膜外腔给予了哌卡因(B2组)。B1和B2组均给予0.75%丁哌卡因1~1.5mg·kg-1,L组给予2%利多卡因4~4.5mg·kg-1。采用高效液相色谱(HPLC)测定硬膜外给药后血浆药物浓度。结果表明三组病例血药浓度均在安全范围内。B1组的血药浓度达高峰时间(Tpeak)和脐静脉与母体血药浓度比(UV/MV)值均小于L组,表明丁哌卡因在硬膜外腔的吸收比利多卡因快,且透过胎盘屏障的药量小于利多卡因,新生儿Apgar评分在娩出后5分钟均为10分。B1组的药代动力学参数与B2组基本相似。结论:剖宫产手术硬膜外腔给予临床剂量的局麻药是安全的。 相似文献
23.
A number of cross-over studies on sedation in outpatient oral surgery investigated the quality of sedation produced by intravenous or rectal administration of diazepam. The sedation methods were equally efficient with a mean dose of 0.24 mg/kg (range 0.1–0.4) for i.v. administration and 0.53 mg/kg (range 0.5–0.6) for rectal administration. Eighty-five percent of the patients preferred surgery under sedation and local anaesthesia to local anaesthesia alone. The patients preferred the session in which they experienced stronger sedation, regardless of the route of administration. 相似文献
24.
Norethisterone enanthate (NET-En), an established intramuscular long-acting contraceptive agent, has previously been shown to be effective in inhibiting fertility in two rodent species even 4 days after oral ingestion. Pharmacokinetics of NET and NET-En were studied after oral and intramuscular doses in two animal species and a few women. The results suggest that the NET-En was absorbed within a day in all the species after oral dose. The estimates of relative bioavailability ranged from 13 to 51% in rabbits, monkeys, and women. The elimination half-life was 5–10 days. The presence of the active component, NET, in the circulation over the experimental period of 15 days suggests that NET-En could be useful as a long-acting oral pill. The suppression of progesterone levels during the luteal phase of menstrual cycle in women also supports this finding. 相似文献
25.
Akosua N.J.A. de Groot Pieter W.J. van Dongen Tom B. Vree Tom K.A.B. Eskes 《European journal of obstetrics, gynecology, and reproductive biology》1995,60(2):101-107
Objective: To study the pharmacodynamic and pharmacokinetic properties of oral and intravenous methylergometrine upon uterine motility during menstruation. Study-design: Intra-uterine pressure was measured in six volunteers with a fluid-filled sponge-tipped catheter during menstruation. Methylergometrine was given orally (0.5 mg) or intravenously (0.2 mg) in a cross-over design. Results: After intravenous administration, a fast increase of the frequency of uterine contractions and basal tone occurred with a decrease of amplitude, lasting at least 30 min. Oral administration had a late and less marked effect on uterine motility. An intravenous dose administered 24 h after an oral dose had no effect on uterine motility. Pharmacokinetic data, such as the maximum plasma concentration (Cmax), the time at which Cmax is reached (tmax) and the half-life of absorption (t1/2abs) also demonstrated large individual variations after oral administration. Conclusion: Oral administration of methylergometrine had an unpredictable and late effect on uterine motility on the menstruating uterus, probably due to an unpredictable bioavailability, in contrast with the fast and predictable effect after intravenous administration. 相似文献
26.
The pharmacokinetics and haemodynamic effects of isosorbide dinitrate (ISDN) have been investigated following administration of single doses as a sublingual (SL) spray (2.5 mg), sublingual tablet (5 mg) and peroral tablet (10 mg) in a randomised, placebo-controlled double-blind cross-over trial in 16 healthy volunteers.After the sublingual spray Cmax was higher (39.0 ng·ml-1) and tmax was shorter (3.9 min) than after the sublingual (22.8 ng·ml-1 and 13.8 min) and peroral (16.9 ng·ml-1 and 25.6 min) tablets. The AUC of ISDN did not differ following any of the three formulations (1031; 879; 997 ng·ml-1·min, for the spray, SL tablet and PO-tablet, respectively). Mononitrate metabolites of ISDN (IS-2-MN and IS-5-MN) and total nitrates in plasma increased in proportion to the administered dose. This indicates that the fraction of the dose absorbed was the same for all the formulations but that the extent of first-pass metabolism increased in the order sublingual spray < sublingual tablet < peroral tablet. Thus, compared to the spray, the relative bioavailability of ISDN was 48% and 28% from the sublingual and peroral tablets, respectively.The haemodynamic effects were quantified using the a/b ratio of the finger pulse wave and the systolic blood pressure and heart rate under orthostatic conditions. For the a/b ratio of the finger pulse, the maximal effect was higher (emax=130%) and the time to emax (temax) shorter (16.6 min) after the spray than the sublingual tablet (84.4% and 25.5 min) or peroral tablet (90.2 and 31.3 min). The onset of effect was within 3, 5 and 7.5 min after the spray, sublingual and peroral tablets, respectively. A larger change in the orthostatically-induced decrease in systolic blood pressure and increase in heart rate was obtained following peroral than sublingual administration despite the similar plasma concentrations of ISDN. This probably reflects the larger amount of pharmacodynamically active mononitrate metabolites formed after oral dosing. The integrated effect following administration of 2.5 mg ISDN as spray was similar to that of a sublingual tablet of 5 mg. 相似文献
27.
Gunilla Movin-Osswald Per Karlsson Margareta Hammarlund-Udenaes Lars Farde 《Psychopharmacology》1994,114(2):248-256
The D2-dopamine receptor antagonist raclopride was administered to eight healthy male subjects, who had previously experienced akathisia following antipsychotic drugs. The influence of administration rate on onset, severity and duration of akathisia and on prolactin response was studied. Raclopride 3,5 or 9 mg or placebo (P) was administered as single IV infusions during 10 min (R10 min/3 mg), 1 h (R1h/5 mg) or 4 h (R4h/9 mg) according to a randomized double-blind design. Despite a 24-fold difference in administration rate a similar peak raclopride concentration of about 350 nmol/l was obtained after all three infusions. Three of the eight subjects experienced akathisia following R10 min/3 mg and R1h/5 mg, respectively. After R4h/9 mg seven subjects experienced akathisia of longer duration but not more severe than after the short infusions. The incidence and duration of akathisia seem to be mainly related to the plasma raclopride concentrations over time, whereas the rate of administration might be more important for the severity. A maximal prolactin response was induced which was not markedly affected by the rate of administration. 相似文献
28.
Self-expanding mesh stent for endoscopic palliation of rectal obstructing tumors: a preliminary report 总被引:2,自引:0,他引:2
Summary The endoscopic insertion of self-expanding mesh stents in four patients affected by obstructing rectal malignant tumors is reported. The preliminary experience shows that, in the short term, normal defecation was achieved, with no complications. Longer follow-up is necessary to evaluate the duration and the quality of the palliative effect. 相似文献
29.
R. Janknegt 《Pharmacy World & Science》1990,12(3):81-90
The microbiological, pharmacokinetic, toxicological and clinical aspects of aminoglycosides are reviewed. Aminoglycosides still have an important place in serious infections in neutropenic patients, endocarditis andPseudomonas aeruginosa infections, all in combination with beta-lactams. Monotherapy (with streptomycin) is indicated in less common diseases like tularaemia and bubonic plague. Several experimental studies support a oncedaily dosing regimen for aminoglycosides (comparable or better efficacy with less ototoxicity and nephrotoxicity). Only a very limited number of prospective comparative studies have been performed, and much more data on efficacy, development of resistance and toxicity is needed before once-daily administration can be recommended. The choice of an aminoglycoside should be based primarily on the local sensitivity patterns and cost. Differences in ototoxicity and nephrotoxicity are usually minor. If the acquisition costs of amikacin decline, it is to be expected that amikacin will be the aminoglycoside of choice. 相似文献
30.
低抗凝肝素来源低分子肝素口服制剂的研究 总被引:4,自引:3,他引:1
以生产肝素的副产品——低抗凝肝素为原料,采用亚硝酸控制解聚法制得了低分子肝素,分子量为5300,抗凝活性为39.2u/mg,测定了理化指标。以对家兔实验性血栓形成的影响为药效学指标,确定低分子肝素口服制剂的处方组成为低分子肝素、油酸、牛胆盐。研究了所制备的低分子肝素胶囊对家兔血液流变学及血栓形成的影响,并试用于部分动脉粥样硬化症志愿者,表明该胶囊可有效地改善家免和动脉粥样硬化症志愿者血液流变性质,抑制血栓形成。 相似文献